Meta-analysis suggests association of L-myc EcoRI polymorphism with cancer prognosis

Clinical Cancer Research

Volumn 10, Issue 14, 2004, Pages 4769-4775

  Spinola, Monica ^a   Pedotti, Paola ^b   Dragani, Tommaso A ^a   Taioli, Emanuela ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ALLELE; CANCER GENETICS; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; ECORI GENE; ETHNOLOGY; GENE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTRON; L MYC GENE; LUNG CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYSTEMATIC REVIEW; TUMOR RECURRENCE;

ALLELES; BINDING SITES; DEOXYRIBONUCLEASE ECORI; DISEASE PROGRESSION; GENE FREQUENCY; GENOTYPE; HUMANS; INTRONS; LUNG NEOPLASMS; NEOPLASMS; POLYMORPHISM, GENETIC; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 3242730200     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0055     Document Type: Review

References (63)

1. Houlston RS, Tomlinson IP. Genetic prognostic markers in colorectal cancer. Mol Pathol 1997;50:281-8.
2. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer 2002;2:210-9.
3. Aarnio M, Mustonen H, Mecklin JP, Jarvinen HJ. Prognosis of colorectal cancer varies in different high-risk conditions. Ann Med 1998;30:75-80.
4. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene 1999;18:3004-16.
5. Cole MD, McMahon SB. The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation. Oncogene 1999;18:2916-24.
6. Kawashima K, Shikama H, Imoto K, et al. Close correlation between restriction fragment length polymorphism of the L-MYC gene and metastasis of human lung cancer to the lymph nodes and other organs. Proc Natl Acad Sci USA 1988;85:2353-6.
7. Shih CM, Kuo YY, Wang YC, et al. Association of L-myc polymorphism with lung cancer susceptibility and prognosis in relation to age-selected controls and stratified cases. Lung Cancer 2002;36:125-32.
8. Ge H, Lam WK, Lee J, Wong MP, Yew WW, Lung ML. Analysis of L-myc and GSTM1 genotypes in Chinese non-small cell lung carcinoma patients. Lung Cancer 1996;15:355-66.
9. Tefre T, Borresen AL, Aamdal S, Brogger A. Studies of the L-myc DNA polymorphism and relation to metastasis in Norwegian lung cancer patients. Br J Cancer 1990;61:809-12.
10. Spinola M, Nomoto T, Manenti G, et al. Linkage disequilibrium pattern in the L-myc gene in Italian and Japanese non-small-cell lung-cancer patients. Int J Cancer 2001;95:329-31.
11. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003;33:177-82.
12. Weir BS. Genetic data analysis 2: methods for discrete population genetic data. Sunderlands, UK: Sinauer Associates, Inc., 1996.
13. Kawashima K, Nomura S, Hirai H, et al. Correlation of L-myc RFLP with metastasis, prognosis and multiple cancer in lung-cancer patients. Int J Cancer 1992;50:557-61.
14. Suzuki H, Yamashiro K. L-myc restriction fragment length polymorphism and histological pattern of invasion in lung adenocarcinoma. Oncol Rep 2002;9:345-7.
15. Fong KM, Kida Y, Zimmerman PV, Smith PJ. MYCL genotypes and loss of heterozygosity in non-small-cell lung cancer. Br J Cancer 1996;74:1975-8.
16. Taioli E, Bonassi S. Methodological issues in pooled analysis of biomarker studies. Mutat Res 2002;512:85-92.
17. d'Errico A, Malats N, Vineis P, Boffetta P. Review of studies of selected metabolic polymorphisms and cancer. In: Vineis P, Malats N, Lang M, et al., editors. Metabolic polymorphisms and susceptibility to cancer. Vol 148. Lyon: IARC Scientific Publications; 1999. p 323-93.
18. Houlston RS. CYP1A1 polymorphisms and lung cancer risk: a meta-analysis. Pharmacogenetics 2000;10:105-14.
19. Ntais C, Polycarpou A, Ioannidis JP. Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomark Prev 2003;12:120-6.
20. Zimmerman KA, Yancopoulos GD, Collum RG, et al. Differential expression of myc family genes during murine development. Nature (Lond) 1986;319:780-3.
21. Makela TP, Saksela K, Alitalo K. Amplification and rearrangement of L-myc in human small-cell lung cancer. Mutat Res 1992;276:307-15.
22. Dunning AM, Durocher F, Healey CS, et al. The extent of linkage disequilibrium in four populations with distinct demographic histories. Am J Hum Genet 2000;67:1544-54.
23. Abecasis GR, Noguchi E, Heinzmann A, et al. Extent and distribution of linkage disequilibrium in three genomic regions. Am J Hum Genet 2001;68:191-7.
24. Clark AG, Nielsen R, Signorovitch J, et al. Linkage disequilibrium and inference of ancestral recombination in 538 single-nucleotide polymorphism clusters across the human genome. Am J Hum Genet 2003;73:285-300.
25. Haberer G, Kieber JJ. Cytokinins. New insights into a classic phytohormone. Plant Physiol 2002;128:354-62.
26. Golovko A, Hjalm G, Sitbon F, Nicander B. Cloning of a human tRNA isopentenyl transferase. Gene (Amst) 2000;258:85-93.
27. Makela TP, Shiraishi M, Borrello MG, Sekiya T, Alitalo K. Rearrangement and co-amplification of L-myc and rfl in primary lung cancer. Oncogene 1992;7:405-9.
28. Kim JO, Nau MM, Allikian KA, et al. Co-amplification of a novel cyclophilin-like gene (PPIE) with L-myc in small cell lung cancer cell lines. Oncogene 1998;17:1019-26.
29. Chenevix-Trench G, Southall M, Kidson C. Restriction fragment length polymorphisms of L-myc and myb in human leukaemia and lymphoma in relation to age-selected controls. Br J Cancer 1989;60:872-4.
30. Kakehi Y, Yoshida O. Restriction fragment length polymorphism of the L-myc gene and susceptibility to metastasis in renal cancer patients. Int J Cancer 1989;43:391-4.
31. Kakehi Y, Taki Y, Yoshida O. Restriction fragment length polymorphism of the L-myc gene and susceptibility to metastasis in genitourinary cancers. Urol Int 1991;47:86-9.
32. Saranath D, Panchal RG, Nair R, Mehta AR, Sanghavi V, Deo MG. Restriction fragment length polymorphism of the L-myc gene in oral cancer patients. Br J Cancer 1990;61:530-3.
33. Ishizaki K, Kato M, Ikenaga M, Honda K, Ozawa K, Toguchida J. Correlation of L-myc genotypes to metastasis of gastric cancer and breast cancer. J Natl Cancer Inst (Bethesda)1990;82:238-9.
34. Kato M, Toguchida J, Honda K, et al. Elevated frequency of a specific allele of the L-myc gene in male patients with bone and soft-tissue sarcomas. Int J Cancer 1990;45:47-9.
35. Tamai S, Sugimura H, Caporaso NE, et al. Restriction fragment length polymorphism analysis of the L-myc gene locus in a case-control study of lung cancer. Int J Cancer 1990;46:411-5.
36. Weston A, Caporaso NE, Perrin LS, et al. Relationship of H-ras-1, L-myc, and p53 polymorphisms with lung cancer risk and prognosis. Environ Health Perspect 1992;98:61-7.
37. Dolcetti R, Pelucchi S, Maestro R, Rizzo S, Pastore A, Boiocchi M. Proto-oncogene allelic variations in human squamous cell carcinomas of the larynx. Eur Arch Otorhinolaryngol 1991;248:279-85.
38. Champeme MH, Bieche I, Latil A, Hacene K, Lidereau R. Association between restriction fragment length polymorphism of the L-myc gene and lung metastasis in human breast cancer. Int J Cancer 1992;50:6-9.
39. Murakami T, Ohmori H, Katoh T, et al. Differences of L-myc polymorphic patterns of neuroblastoma in patients under 1 year versus older ages: a preliminary report. J Pediatr Surg 1992;27:1442-6.
40. Taylor JA, Bell DA, Nagorney D. L-myc proto-oncogene alleles and susceptibility to hepatocellular carcinoma. Int J Cancer 1993;54:927-30.
41. Young J, Buttenshaw R, Butterworth L, et al. Association of the SS genotype of the L-myc gene and loss of 18q sequences with a worse clinical prognosis in colorectal cancers. Oncogene 1994;9:1053-6.
42. Crossen PE, Morrison MJ, Colls BM. Increased frequency of the S allele of the L-myc oncogene in non-Hodgkin's lymphoma. Br J Cancer 1994;69:759-61.
43. Weston A, Ling-Cawley HM, Caporaso NE, et al. Determination of the allelic frequencies of an L-myc and a p53 polymorphism in human lung cancer. Carcinogenesis (Lond) 1994;15:583-7.
44. Zborovskaya I, Gasparian A, Kitaeva M, et al. Simultaneous detection of genetic and immunological markers in non-small cell lung cancer: prediction of metastatic potential of tumor. Clin Exp Metastasis 1996;14:490-500.
45. Presti JC Jr, Hinckley J, Reuter VE. L-MYC allelotype in renal cell carcinoma. Cancer Genet Cytogenet 1996;88:66-8.
46. Hsieh LL, Huang RC, Yu MW, Chen CJ, Liaw YF. L-myc, GST M1 genetic polymorphism and hepatocellular carcinoma risk among chronic hepatitis B carriers. Cancer Lett 1996;103:171-6.
47. Shibuta K, Mori M, Haraguchi M, Yoshikawa K, Ueo H, Akiyoshi T. Association between restriction fragment length polymorphism of the L-myc gene and susceptibility to gastric cancer. Br J Surg 1998;85:681-4.
48. Fernandez T, Saranath D, Advani SH, Deo MG, Soman CS. Restriction fragment length polymorphism of the L-myc oncogene in non-Hodgkin's lymphoma patients from India. Cancer Lett 1998;125:165-9.
49. Chernitsa OI, Togo AV, Shutkin VA, Hanson KP, Imyanitov EN. S allele of L-MYC oncogene is associated with metastatic lung cancer in patients from Moldova. Eur J Cancer 1998;34:1816-7.
50. Ejarque MJ, Vicente M, Bernues M, et al. Restriction fragment length polymorphism of the L-myc gene is not a prognostic factor in bladder cancer patients. Br J Cancer 1999;79:1855-8.
51. Kondratieva TV, Imyanitov EN, Togo AV, et al. L-MYC and GSTM1 polymorphisms are associated with unfavourable clinical parameters of gliomas. J Exp Clin Cancer Res 2000;19:197-200.
52. Togo AV, Suspitsin EN, Grigoriev MY, et al. L-myc polymorphism in cancer patients, healthy blood donors and elderly, tumor-free individuals in Russia. Int J Cancer 2000;85:747-50.
53. Shibuta K, Inoue H, Sato K, et al. L-myc restriction fragment length polymorphism in Japanese patients with esophageal cancer. Jpn J Cancer Res 2000;91:199-203.
54. Kumimoto H, Hamajima N, Nishizawa K, et al. Different susceptibility of each L-myc genotype to esophageal cancer risk factors. Jpn J Cancer Res 2001;92:735-9.
55. Yaylim I, Isbir T, Ozturk O, et al. Is there any correlation between restriction fragment length polymorphism of the L-MYC gene and metastasis of human nonsmall cell lung cancer? Cancer Genet Cytogenet 2002;134:118-22.
56. Kumimoto H, Hamajima N, Nishimoto Y, et al. L-myc genotype is associated with different susceptibility to lung cancer in smokers. Jpn J Cancer Res 2002;93:1-5.
57. Dlugosz A, Adler G, Ciechanowicz A, Jaroszewicz-Heigelmann H, Starzynska T. EcoRI polymorphism of the L-myc gene in gastric cancer patients. Eur J Gastroenterol Hepatol 2002;14:1231-5.
58. Isbir T, Yaylim I, Arikan S, et al. Close correlation between restriction fragment length polymorphism of L-myc gene and susceptibility to gastric cancer. Cancer Detect Prev 2002;26:454-7.
59. Isbir T, Yayllm I, Arikan S, Kucucuk S, Camlica H. Increased frequency of the S-allele of the L-myc oncogene in breast cancer. Mol Med 2002;8:521-4.
60. Mironov NM, Aguelon AM, Potapova GI, Gorbunov OV, Klimenkov AA, Yamasaki H. L-myc allele polymorphism and prognosis for metastases in Russian gastric cancer patients. Eur J Cancer 1994;30A:1732.
61. Kato S, Onda M, Matsukura N, et al. Genetic polymorphisms of the cancer related gene and Helicobacter pylori infection in Japanese gastric cancer patients. An age and gender matched case-control study. Cancer (Phila) 1996;77:1654-61.
62. Ko JM, Cheung MH, Wong C, et al. L-myc genotypes in Hong Kong Chinese colorectal carcinoma patients. Oncology Rep 1999;6:441-4.
63. Mendoza C, Sato H, Hiyama K, et al. Allelotype and loss of heterozygosity around the L-myc gene locus in primary lung cancers. Lung Cancer 2000;28:117-25.